The "Product of a Village": FDA as a Partner in Evidence Generation
- PMID: 39132516
- PMCID: PMC11308859
- DOI: 10.1016/j.jscai.2022.100561
The "Product of a Village": FDA as a Partner in Evidence Generation
Keywords: Atrial fibrillation; left atrial appendage occlusion; regulatory; sex.
Comment on
References
-
- Jiang H., Zheng Q., Cheng Y.J., et al. Sex-specific long-term outcomes of Watchman left atrial appendage closure for stroke prevention in atrial fibrillation. J Soc Cardiovasc Angiogr Interv. 2023;2(1):100541.
-
- Osman M., Patel B., Munir M.B., et al. Sex-stratified analysis of the safety of percutaneous left atrial appendage occlusion. Catheter Cardiovasc Interv. 2021;97(5):885–892. - PubMed
-
- Alkhouli M., Russo A.M., Thaler D., et al. Sex differences in safety and effectiveness of LAAO: insights from the Amulet IDE trial. JACC Cardiovasc Interv. 2022;15(21):2143–2155. - PubMed
-
- Reddy V.Y., Sievert H., Halperin J., et al. Committee PAS and Investigators Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–1998. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
